Lonza grows hepatocytes portfolio

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/vshivkova)
(Image: Getty/vshivkova)
Lonza has added to its hepatocytes portfolio to provide researchers with the foundation to create “more physiologically relevant” in vitro models for liver disease research.

The expanded portfolio now includes hepatic stellate cells, Kupffer cells, and liver-derived endothelial cells, according to the company.

“There are many transformative efforts ongoing to create and validate in vitro human models for better diagnostics and treatments of liver disease and toxicity,”​ Maureen Bunger, PhD, product manager, ADME/tox solutions, Lonza Biosciences, told us.

Offering high quality Kupffer, stellate, and liver endothelial cells in addition to hepatocytes in support of these models can accelerate the impact they may have on human health,”​ she added.

Hepatic non-parenchymal cells are involved in normal liver function, including transport, metabolism and growth – and also play a role in the immune response. 

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related product

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q² Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Related suppliers

Follow us

Products

View more

Webinars